Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far?
Barbara Fischer1, Marin Marinov, Alexandre Arcaro
1Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Steinwiesstrasse 75, CH-8032 Zurich, Switzerland. Barbara.Fischer@kispi.unizh.ch
Abstract:
Small cell lung cancer (SCLC) is an aggressive form of lung cancer, which represents 13% of all cases and is strongly associated with cigarette smoking. The survival of SCLC patients is dismal and has not greatly improved in the last 20 years, despite advances in chemotherapy regimens and a better understanding of SCLC biology. The development of resistance to chemotherapy and metastasis are commonly recognized as important causes of poor clinical outcome in SCLC. Targeting receptor tyrosine kinase (RTK) signalling represents an attractive approach to develop new drugs for SCLC, in view of the accumulating data demonstrating that polypeptide growth factors play a key role in driving SCLC cell proliferation, chemoresistance and metastasis. The insulin-like growth factor-I receptor (IGF-IR), c-Kit, vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) have been identified as potential drug targets in SCLC. Moreover, downstream signalling mediators of RTKs, such as phosphoinositide 3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) may also represent attractive candidate molecules for anti-cancer therapies in SCLC. Here we will review the available data concerning results with RTK inhibitors in SCLC and the clinical trials undertaken to investigate the potential of these compounds as anti-tumour agents in SCLC.
Insights
Small cell lung cancer (SCLC) remains aggressive with poor survival. Targeting receptor tyrosine kinase (RTK) signaling pathways offers a promising strategy for developing novel anti-cancer therapies to overcome chemoresistance and metastasis in SCLC patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Small cell lung cancer (SCLC) is an aggressive malignancy, accounting for 13% of lung cancer cases, strongly linked to smoking.
- Patient survival in SCLC has seen minimal improvement over two decades, with chemotherapy resistance and metastasis being key challenges.
- Polypeptide growth factors critically influence SCLC proliferation, chemoresistance, and metastasis, highlighting receptor tyrosine kinases (RTKs) as potential therapeutic targets.
Purpose of the Study:
- To review current data on receptor tyrosine kinase (RTK) inhibitors in SCLC.
- To examine clinical trials investigating RTK inhibitors as anti-cancer agents for SCLC.
- To explore the role of RTK signaling pathways and their downstream mediators in SCLC progression and treatment.
Main Methods:
- Literature review of preclinical and clinical studies on RTK inhibitors in SCLC.
- Analysis of data on identified RTK targets including IGF-IR, c-Kit, VEGFR, and EGFR.
- Examination of downstream signaling pathways such as PI3K/Akt and mTOR in the context of SCLC therapy.
Main Results:
- Several RTKs (IGF-IR, c-Kit, VEGFR, EGFR) are implicated in SCLC growth, chemoresistance, and metastasis.
- Downstream signaling mediators like PI3K/Akt and mTOR are also potential therapeutic targets.
- Clinical trials are evaluating the efficacy of various RTK inhibitors in SCLC patients.
Conclusions:
- Targeting RTK signaling pathways presents a viable strategy for novel SCLC drug development.
- Inhibitors of RTKs and their downstream effectors hold promise for improving clinical outcomes in SCLC.
- Further clinical investigation of RTK-targeted therapies is crucial for advancing SCLC treatment.
